772-79-2 Usage
Description
4-Chlorophenyl phosphorodichloridate is an organophosphorus compound that serves as a versatile phosphorylation agent in various chemical reactions. It is characterized by its ability to form stable phosphorus-carbon bonds, making it a valuable intermediate in the synthesis of a wide range of organic compounds.
Uses
Used in Pharmaceutical Industry:
4-Chlorophenyl phosphorodichloridate is used as a reactant for the preparation of antimicrobial agents, contributing to the development of new drugs to combat resistant bacterial strains. Its ability to form stable bonds with biologically active molecules enhances the effectiveness of these agents.
Used in Antioxidant Applications:
In the field of antioxidants, 4-Chlorophenyl phosphorodichloridate is utilized as a reactant for the synthesis of antioxidant agents. These antioxidants are essential in various industries, including food, cosmetics, and pharmaceuticals, to prevent oxidation and extend the shelf life of products.
Used in Antitumor Applications:
4-Chlorophenyl phosphorodichloridate is employed as a reactant in the preparation of antitumor agents, playing a crucial role in the development of novel cancer therapies. Its unique chemical properties allow for the creation of compounds that can target and inhibit the growth of cancer cells.
Used in Nucleotide Anti-Viral Prodrug Development:
In the area of anti-viral drug development, 4-Chlorophenyl phosphorodichloridate is used as a reactant for the synthesis of nucleotide anti-viral prodrugs. These prodrugs are designed to be activated within the body, providing a targeted approach to treating viral infections and minimizing side effects.
Overall, 4-Chlorophenyl phosphorodichloridate is a valuable chemical intermediate with diverse applications across various industries, particularly in the development of pharmaceuticals and other specialty chemicals. Its unique properties and reactivity make it an essential component in the synthesis of a wide range of compounds with potential therapeutic and commercial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 772-79-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,7 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 772-79:
(5*7)+(4*7)+(3*2)+(2*7)+(1*9)=92
92 % 10 = 2
So 772-79-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H4Cl3O2P/c7-5-1-3-6(4-2-5)11-12(8,9)10/h1-4H
772-79-2Relevant articles and documents
Prodrug compound and application ofprodrug compound in treatment of cancer
-
Paragraph 0160-0161, (2021/03/06)
The present invention provides a compound indicated by a formula (I), pharmaceutically acceptable salts or esters thereof, a pharmaceutical composition of the compound, and application of the compoundand the pharmaceutical composition in the inhibition or regulation of the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.
A convenient solid phase approach to obtain lipophilic 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides
Dovydenko, Ilya S.,Kupryushkin, Maxim S.,Pyshnyi, Dmitrii V.,Apartsin, Evgeny K.
, p. 102 - 111 (2018/02/16)
This paper explores the potential of a modified phosphotriester approach to the synthesis of 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides. The modification of 5′-deprotected support-bound oligonucleotides is done in two steps: i) conversion of the 5′-OH group of an oligonucleotide into an activated phosphodiester, and ii) treatment of the activated phosphodiester with an aminocompound. The approach is efficient and compatible with conventional solid phase oligonucleotide synthesis. It can be used for the conjugation of therapeutically relevant oligonucleotides with functional moieties or carrier constructions, which are to be removed after endocytosis.
SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
-
Paragraph 0699; 0705; 0706; 0709, (2016/03/11)
Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.